As we barrel into the second half of the year, it’s time to look back and make sense of what just happened. Download our infographic for a quick, data-packed overview of the biopharma and medtech landscape in H1. From M&A activity to IPO hopefuls, venture financing disparity to stock price winners and losers – it’s […]
Share:
As we barrel into the second half of the year, it’s time to look back and make sense of what just happened. Download our infographic for a quick, data-packed overview of the biopharma and medtech landscape in H1. From M&A activity to IPO hopefuls, venture financing disparity to stock price winners and losers – it’s all in there.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
